Nestlé Health Science (SWX:NESN) plans on taking a leading role in commercializing Seres Therapeutics’ (NSDQ:MCRB) experimental oral microbiome drug SER-109 for recurrent Clostridioides difficile infection (CDI). The infection from the bacteria can lead to diarrhea and, in severe cases, severe colon damage and life-threatening inflammation. More than 20,000 Americans die each year from CDI, according…